viewRevive Therapeutics

Revive Therapeutics updates on potential COVID-19 treatment, and its oral form of magic mushrooms

Revive Therapeutics Ltd. (CSE: RVV) (OTCMKTS: RVVTF) CEO Michael Frank and Psilocin Pharma Founder Derrick Welsh explain to Proactive how the Toronto-based company is currently advancing to a Phase 3 clinical trial to treat the coronavirus with a rheumatoid arthritis therapy, in addition to its efforts to advance its oral dosage forms of psilocybin.

Psilocybin is the chemical found in magic mushrooms, which may be used to treat a variety of diseases and disorders.

Welsh says psilocybin has the potential to be as popular as cannabis in the biopharma space.

Quick facts: Revive Therapeutics

Price: 0.275 CAD

Market: CSE
Market Cap: $45.09 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Revive Therapeutics named herein, including the promotion by the Company of Revive Therapeutics in any Content on the Site, the Company...


Revive Therapeutics: Analyst sees 'substantial upside potential' as key...

Proactive Research analyst Ed Stacey says Revive Therapeutics (CSE:RVV)(OTCQB:RVVTF) is a speciality life sciences company focussed on repurposing drugs for rare and infectious diseases and has a pipeline of of three main platforms. One of them is Bucillamine (BUC) which is a medication with a...

on 06/30/2020

2 min read